Friday Five: More Fallout From Valeant Debacle
Two figures are heading toward the exit as the embattled pharma firm's saga continues. Plus, our take on Apple's product tune-up, and more.
Christine Benz: Hi, I'm Christine Benz for Morningstar.com. Welcome to The Friday Five. Joining me to discuss five of the top business and market headlines from the past week is Morningstar markets editor Jeremy Glaser.
Jeremy, thank you for being here.
Jeremy Glaser does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.